We believe PressureSafe can become the new standard of care in the detection of pressure injuries, and we are very pleased to share this data as we plan to file for U.S. FDA approval and subsequent market launch following regulatory clearance,” said Oded Bashan, IR-MED executive chair and interim CEO. “We believe that the healthcare economics benefits PressureSafe offers combined with the improvement in patient outcomes is a powerful combination for rapid market adoption.”